Lijun Li

Title: Lijun Li: Innovator in Pharmaceutical Processes

Introduction

Lijun Li is a notable inventor based in Dongguan, China. He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of prasugrel, a medication used to prevent blood clots. His innovative approach has led to advancements in both the efficiency and safety of drug production.

Latest Patents

Lijun Li holds a patent for a process titled "Process for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride." This patent discloses a method for preparing prasugrel using solvents that have low boiling points and low toxicity. The process not only avoids harmful solvents but also addresses the thermal instability of prasugrel, resulting in a higher yield of over 85% and a purity exceeding 99.5%. The novel crystalline forms of prasugrel hydrochloride, identified as crystalline forms H1, H2, and H3, exhibit excellent oral absorbability and low toxicity, making them suitable for treating thrombotic conditions.

Career Highlights

Throughout his career, Lijun Li has worked with prominent pharmaceutical companies, including Sunshine Lake Pharma Co., Ltd. and Yichang Changjiang Pharmaceutical Co., Ltd. His work has been instrumental in developing safer and more effective pharmaceutical processes.

Collaborations

Lijun Li has collaborated with several professionals in the field, including Hailong Wang and Zhongqing Wang. These collaborations have contributed to the advancement of his research and the successful development of his patented processes.

Conclusion

Lijun Li's innovative work in the preparation of prasugrel has made a significant impact on the pharmaceutical industry. His contributions not only enhance drug safety and efficacy but also pave the way for future advancements in medication development.